Dengue Vaccine Market by End-user and Geography - Forecast and Analysis 2021-2025

The dengue vaccine market share is expected to increase by USD 132.9 million from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 18%.

This dengue vaccine market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers dengue vaccine market segmentations by end-user (government institutions, hospitals, and NGOs) and geography (North America, Asia, Europe, and ROW). The dengue vaccine market report also offers information on several market vendors, including BioNet-Asia Co. Ltd., Chula VRC, Codagenix Inc., Emergex Vaccines Holding Ltd., GeneOne Life Science Inc., Imutex Ltd., KM Biologics Co. Ltd., Medigen Biotechnology Corp., Najít Technologies Inc., and Sanofi SA among others.

What will the Dengue Vaccine Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Dengue Vaccine Market Size for the Forecast Period and Other Important Statistics

 

Dengue Vaccine Market: Key Drivers, Trends, and Challenges

Based on our research output, there has been a neutral impact on the market growth during and post COVID-19 era. The rapid growth in disease prevalence is notably driving the dengue vaccine market growth, although factors such as regulatory hurdles in vaccine penetration may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the dengue vaccine industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Dengue Vaccine Market Driver

One of the key factors driving the dengue vaccine market growth is the rapid growth in disease prevalence. The factors contributing to the rise in dengue cases include an increase in population density and global warming. As per the NIH, 3.6 billion people that reside in tropical and subtropical regions are at risk of dengue transmission. Global estimates vary, but nearly 0.05 to 0.2 billion cases of dengue infections are reported annually. As per the NIH, the upper bound total was 3.97 billion for people at risk of dengue in 128 countries globally. The actual incidence cases of dengue are expected to be significantly higher than the reported cases due to poor disease surveillance, diagnostic difficulties, and less reported dengue cases. The exact prevalence of dengue and its economic effect is unknown. More than 125 countries are believed to be dengue-endemic globally. Thus, the rise in the prevalence rate of the disease will drive the market during the forecast period.

Key Dengue Vaccine Market Trend

Growing awareness is the major trend influencing dengue vaccine market growth. The awareness about dengue prevention is rising globally, with various initiatives being taken by both government and non-government bodies. For instance, in 2015, a large-scale campaign against dengue was launched in Malaysia, a country susceptible to the disease due to its geographic location, to increase awareness and provide prophylaxis. In India, with half the population at risk, the central government has asked all the state governments to initiate aggressive campaigns for improving public awareness about the prophylaxis and management of mosquito-borne diseases. In Singapore, an educational campaign called Be A Wall Against Dengue was launched in June 2015 to increase awareness about dengue and its prevention. The campaign was launched by Sanofi Pasteur in partnership with Ya Kun, a Singaporean chain of mass-market. The growing global awareness about dengue and the need for prophylaxis against the disease will increase the demand for vaccines, thereby leading to the growth of the market.

Key Dengue Vaccine Market Challenge

Regulatory hurdles in vaccine penetration is one of the key challenges hindering the dengue vaccine market growth. Vendors are facing difficulty in getting approvals for the launch of vaccines in several dengue-endemic countries due to the nature of dengue serotypes in different countries. The circulation of dengue serotypes fluctuates in dengue-endemic regions. Hence, vaccine efficacy must be exhibited against all four serotypes for which region-specific clinical trials are required to be conducted. For the inclusion of vaccines in the public immunization program of any country, demographic efficacy and safety data are required, which require additional clinical trials at regional levels at times to comply with the regulatory requirements. This leads to a delay in the launch of the product, and ultimately the potential sales get affected negatively. With the approval of the vaccines targeted for the eradication of the disease by WHO getting delayed due to additional regulatory requirements, the business potential of the vendors gets adversely affected and serves as a hurdle to market growth.

This dengue vaccine market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.

Parent Market Analysis

Technavio categorizes the global dengue vaccine market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the dengue vaccine market during the forecast period.

Who are the Major Dengue Vaccine Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

• BioNet-Asia Co. Ltd.
• Chula VRC
• Codagenix Inc.
• Emergex Vaccines Holding Ltd.
• GeneOne Life Science Inc.
• Imutex Ltd.
• KM Biologics Co. Ltd.
• Medigen Biotechnology Corp.
• Najít Technologies Inc.
• Sanofi SA

 

This statistical study of the dengue vaccine market encompasses successful business strategies deployed by the key vendors. The dengue vaccine market is fragmented and the vendors are deploying growth strategies such as R&D efforts by companies for new product development to compete in the market.

Product Insights and News

• BioNet-Asia Co. Ltd.  - The company offers Nanotaxi formulated DNA vaccine that induce strong immune response against dengue virus.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The dengue vaccine market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Dengue Vaccine Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the dengue vaccine market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

The report has further elucidated on other innovative approaches being followed by manufacturers to ensure a sustainable market presence.

 

Which are the Key Regions for Dengue Vaccine Market?

For more insights on the market share of various regions Request for a FREE sample now!

52% of the market's growth will originate from North America during the forecast period. US and Mexico are the key markets for dengue vaccine in North America. Market growth in this region will be slower than the growth of the market in Asia regions.

The US could be expected to show interest in introducing dengue vaccines in the country due to proximity to other dengue-endemic countries, thus providing ample growth avenues to the market in the region. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

The outbreak of COVID-19 affected all countries in North America, especially the US. It also had a negative impact on the dengue vaccine market in the region. As of May 13, 2021, more than 33.59 million cases of COVID-19 were reported in the US. A rise in the number of COVID-19 cases in the first quarter of 2020 led to partial lockdowns in several countries, including Canada and Mexico. Thus, various non-urgent treatments and clinical visits were either delayed or canceled. Hence, the adoption of vaccines for dengue declined, which impacted market growth in 2020 and Q1 2021 to some extent. However, by January 2021, lockdown regulations in various countries were relaxed, which led to the resumption of business activities offering essential services. Thus, the resumption of pharmaceutical manufacturing will cater to the demand for dengue vaccines in North America and register accelerating market growth during the forecast period.

What are the Revenue-generating End-user Segments in the Dengue Vaccine Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The dengue vaccine market share growth by the government institutions will be significant during the forecast period. Government bodies carry out programs at the state level as well as at the central level to prevent the disease onset, and that ultimately drives the demand for dengue vaccine and increases the sales potential.

Besides the above-mentioned factors, the post COVID-19 impact has brought forth a slowdown in or fast tracked the demand for the service or product. This report provides an accurate prediction of the contribution of all the segments to the growth of the dengue vaccine market size and actionable market insights on post COVID-19 impact on each segment.

 

Dengue Vaccine Market Scope
Report Coverage	Details
Page number	120
Base year	2020
Forecast period	2021-2025
Growth momentum & CAGR	Accelerate at a CAGR of 18%
Market growth 2021-2025	$ 132.9 million
Market structure	Fragmented
YoY growth (%)	15.50
Regional analysis	North America, Asia, Europe, and ROW
Performing market contribution	North America at 52%
Key consumer countries	US, Mexico, China, Germany, and India
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	BioNet-Asia Co. Ltd., Chula VRC, Codagenix Inc., Emergex Vaccines Holding Ltd., GeneOne Life Science Inc., Imutex Ltd., KM Biologics Co. Ltd., Medigen Biotechnology Corp., Najít Technologies Inc., and Sanofi SA
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Dengue Vaccine Market Report?

• CAGR of the market during the forecast period 2021-2025
• Detailed information on factors that will drive dengue vaccine market growth during the next five years
• Precise estimation of the dengue vaccine market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the dengue vaccine industry across North America, Asia, Europe, and ROW
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of dengue vaccine market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch